NCT02037230View on ClinicalTrials.gov

Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Adenocarcinoma of the Pancreas
Interventions
DRUG

MK-1775

MK-1775 will be given as an oral capsule on days 1 and 2, and on days 8 and 9 of every 3-week cycle .

DRUG

Gemcitabine

Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1 and 8 of a 3 -week treatment cycle.

RADIATION

Radiation Therapy

52.5Gy in 25 fractions (2.1Gy/fraction), using intensity modulated radiation therapy (IMRT). Radiation therapy will be administered after chemotherapy.

Trial Locations (1)

48109

University of Michigan Hospital, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT02037230 - Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas | Biotech Hunter | Biotech Hunter